Quality Chemical Industries Limited
Company type | Private |
---|---|
Industry | Pharmaceutical industry |
Founded | July 10, 2005 |
Headquarters | Luzira, Kampala, Uganda |
Key people | Emmanuel Katongole, executive chairman Nevin Bradford, executive director & chief executive officer |
Services | Pharmaceuticals |
Total assets | UGX:209.296 billion (2018)[citation needed] |
Number of employees | 387 (2018)[citation needed] |
Website | Homepage |
Cipla Quality Chemical Industries Limited (CQCIL) is a pharmaceutical manufacturing company in Uganda. According to a 2007 published report, it was the only company in Africa that manufactured triple-combination antiretroviral (ARV) drugs.[1] CQCIL also manufactures the antimalarial drug Lumartem, which contains artemisinin and lumefantrine,[2] and the Hepatitis B generic medicines Texavir and Zentair.[3][4]
Location
CQCIL's pharmaceutical manufacturing plant is located in Luzira, a neighborhood in Nakawa Division in south-eastern Kampala. The plant is approximately 9 kilometres (6 mi), by road, south-east of Kampala's central business district.[5] The coordinates of the plant are 0°18'17.0"N, 32°38'22.0"E (Latitude:0.304723; Longitude:32.639436).[6]
History
In 2004, Quality Chemicals Limited (QCL) convinced Indian drug maker Cipla to enter into a joint venture with QCL and the government of Uganda to establish a pharmaceutical plant in Uganda. Ground was broken in 2005, and the factory was commissioned in 2007,[7] with a capacity of 6 million pills daily.[8]
In 2009, TLG Capital, a London-based private equity company,[9] invested an undisclosed amount of money in the plant.[10] Later, CapitalWorks Investment Partners, a private equity firm based in South Africa, also became a shareholder in the plant.[11] In February 2010, the government of Uganda divested from the plant by selling its shares "at cost" to CQCIL. The transaction was valued at US$5 million.[12]
In February 2011, the owners of the plant announced a US$40 million expansion of the production line to include increased production of ARVs and antimalarial medication. In April 2012, British media reported that CQCIL was in the process of expanding its manufacturing capacity fourfold. The plant had received approval of its processes and products from the World Health Organization. The products were expected to be initially marketed in Burundi, the Democratic Republic of the Congo, Kenya, Rwanda, South Sudan, Tanzania, and Uganda.[12]
According to a 2012 published report, CQCIL was planning to build a second plant next to the first plant, which would raise CQCIL's manufacturing capacity to 18 million pills daily.[13]
As of April 2016, the company's products were marketed in Cameroon, Comoros, Kenya, Namibia, Tanzania, Uganda, and Zambia.[14]
Ownership of pharmaceutical plant
As of April 2017, the shareholding in the pharmaceutical plant was as depicted in the table below:[15] In 2017, the company began to implement plans to list some of its shares on the Uganda Securities Exchange.[16] After the listing, it is expected that the shareholding in the company stock will be as reflected in the table below.[15][17][18][19]
Rank | Name of Owner | % Ownership Pre-IPO | % Ownership Post-IPO |
---|---|---|---|
1 | Meditab Holdings Limited[20] | 51.05[18] | 51.05[18] |
2 | Cipla European Union[18] | 11.25[18] | 0.00[18] |
3 | CapitalWorks Investment Partners | 14.40[21] | 11.11[18] |
4 | TLG Capital (Amistad) | 12.50[22] | 11.50[18] |
5 | Emmanuel Katongole | 3.60[15] | 2.78[18] |
5 | Frederick Kitaka | 3.60[15] | 2.78[18] |
6 | George Baguma | 3.60[15] | 2.78[18] |
7 | Other investors via the Uganda Securities Exchange | 0.00[15] | 18.00[18] |
Total | 100.00 | 100.00 |
- Cipla also owns 51 percent of QCL.[23]
- Until May 2015, QCL owned 22.05 percent of CQCIL.[23] Sometime after that, QCL sold its entire shareholding; 10.8 percent to three of the individual founders and the remaining 11.25 percent to Cipla European Union, thus raising Cipla's shareholding to the pre-IPO level of 62.3 percent.[24]
Governance
The executive chairman of the board of directors of CQCIL is Emmanuel Katongole, who was formerly the managing director of CQCIL. He replaced Francis Kitaka, the first person in eastern Africa to train as a biochemist,[25][26] The managing director of CQCIL is Nevin Bradford.[27]
References
- ^ Charles Wendo (6 October 2007). "ARVs production starts Monday". New Vision. Kampala. Retrieved 23 June 2014.
- ^ Data Key (2011). "Quality Chemical Industries – HIV Drug Plant". Pharmaceutical Technology. Retrieved 23 June 2014.
- ^ "Timeline & Milestones". CQCIl. 2015. Retrieved 10 April 2016.[dead link]
- ^ "Komboa Newsletter" (PDF). CQCIL. December 2015. p. 4. Retrieved 10 April 2016.[dead link]
- ^ "Distance between Post Office Building, Kampala Road, Kampala, Central Region, Uganda and Cipla Quality Chemicals Industries Limited, Port Bell Road, Kampala, Central Region, Uganda". Globefeed.com. 11 June 2016. Retrieved 11 July 2016.
- ^ Google (11 July 2016). "Location of Cipla Quality Chemical Industries Limited Pharmaceutical Factory, Luzira, Nakawa Division, Kampala, Uganda" (Map). Google Maps. Google. Retrieved 11 July 2016.
- ^ Elvis Basudde; Robert Kasozi (31 October 2007). "Kitaka, the brain behind Africa's first ARVs factory". New Vision. Kampala. Retrieved 11 July 2016.
- ^ Tatum Anders (22 November 2007). "Trip into the unknown". Nature. 450 (7169): 471–471. doi:10.1038/450471a.
- ^ "About TLG Capital". TLG Capital. 25 June 2018. Retrieved 25 June 2018.
- ^ "Ugandan project attracts investors". Investment International. 9 September 2009. Retrieved 23 June 2014.
- ^ "Partners". Cipla Quality Chemical Industries Limited.
- ^ a b "Making drugs into profit in Uganda". BBC News. BBC. 9 April 2012. Retrieved 11 July 2016.
- ^ Raymond Baguma (18 May 2012). "Quality Chemicals giving Ugandans fighting chance". New Vision. Retrieved 23 June 2014.
{{cite news}}
: Cite has empty unknown parameter:|1=
(help) - ^ Emmanuel Ainebyoona (9 April 2016). "Uganda exports 70 tonnes of ARVs". Daily Monitor. Kampala. Retrieved 11 July 2016.
- ^ a b c d e f "Cipla Quality Chemical Industries to list 31.1% stake in IPO - report". Kampala: Uganda Business News. 7 April 2017. Retrieved 25 June 2018.
- ^ Michael Wakabi (23 June 2018). "Drug maker CIPLA and telco MTN to list on Uganda bourse". The EastAfrican. Nairobi. Retrieved 24 June 2018.
- ^ P. K. Malinz (2 August 2018). "Uganda's CiplaQCi set for IPO with a valuation of US $12.5 Million". Kampala: Digest Africa Technologies. Retrieved 2 August 2018.
- ^ a b c d e f g h i j k l "Cipla Quality Chemical Industries Limited: Investment Prospectus for Initial Public Offering, July 2018". Cipla Quality Chemical Industries Limited. July 2018. Retrieved 4 August 2018.
- ^ Charles Mpagi (18 August 2018). "Cipla listing on Uganda bourse a key milestone". The EastAfrican. Nairobi. Retrieved 21 August 2018.
- ^ Frederic Musisi (22 November 2013). "Indian firm buys more shares in Quality Chemicals Ltd". Daily Monitor. Kampala. Retrieved 28 October 2016.
- ^ "Press Release: Quality Chemical Industries Limited rebrands following Cipla's increased shareholding" (PDF). Cipla Quality Chemical Industries Limited. 16 July 2014. Retrieved 28 October 2016.[dead link]
- ^ "TLG Capital ups stake in Cipla's Africa JV". Reuters India. 11 July 2011. Retrieved 28 October 2016.
- ^ a b Anuradha Verma (22 May 2015). "Cipla to acquire 51% stake in Ugandan firm Quality Chemicals for $30M". VCCirle.com. Retrieved 4 August 2018.
- ^ Bernard Busuulwa (7 April 2017). "Drug firm CiplaQCIL plans to sell 31pc stake in IPO on Uganda bourse". The EastAfrican. Nairobi. Retrieved 4 August 2018.
- ^ Taddewo Senyonyi (4 January 2014). "Francis X. Kitaka: The Unsung Hero of Uganda's Health And Agricultural Sectors". Kampala: The CEO Magazine. Retrieved 9 April 2016.[dead link]
- ^ "Emmanuel Katongole: The founder of Quality Chemicals". Daily Monitor. Kampala. 18 October 2013. Retrieved 17 March 2015.
- ^ "Board of Directors of CiplaQCIL". Ciplaqcil.co.ug. 30 November 2013. Retrieved 17 March 2015.
{{cite web}}
: Cite has empty unknown parameter:|1=
(help)